Raymond James upgrades BioMarin stock to Strong Buy at USD 109.00

Published on 10/20/2026 at 19:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Raymond James sets a USD 109.00 target after its October 12, 2026 upgrade. BioMarin stock costs EUR 49.79 on October 20, 2026.

Analyst target and royalty agreement

Raymond James upgraded BioMarin to Strong Buy and set a USD 109.00 target on October 12, 2026.
BioMarin agreed to pay Ascendis royalties of 20.00 percent in the United States and 18.00 percent in parts of Europe, Brazil and South Korea.
BioMarin stock costs EUR 49.79 at Lang & Schwarz on October 20, 2026 at 7:20 p.m. CEST.

BMRN, US09061G1013, Illustration mit AI erstellt.

Raymond James upgraded BioMarin Pharmaceutical to Strong Buy and set a USD 109.00 price target on October 12, 2026, according to Investing.com. The target stood 94.99 percent above the Nasdaq price of USD 55.90 at the October 20, 2026 finance snapshot. BioMarin stock was trading at EUR 49.79 at Lang & Schwarz on October 20, 2026 at 7:20 p.m. CEST.

Royalty terms add a second valuation angle

BioMarin had entered a settlement and license agreement with Ascendis Pharma on September 24, 2026. The filing gives Ascendis rights to develop and commercialize products containing TransCon CNP, also known as navepegritide or Yuviwel, while BioMarin receives royalties on future sales, according to the SEC filing.

The royalty rate is 20.00 percent of annual net sales in the United States and 18.00 percent in the European Union, Brazil and South Korea. The agreement also covers patent litigation, with the parties agreeing to dismiss pending cases and ending the prior term sheet.

Nasdaq range remains wide

BioMarin traded at USD 55.90 on the Nasdaq at 1:27 p.m. ET on October 20, 2026. Its 52-week range was USD 49.26 to USD 70.98, placing the latest Nasdaq price 21.25 percent above the low and 21.25 percent below the high. The stock had a market capitalization of USD 10.8 billion and a price-to-earnings ratio of 143.41.

Analyst target meets operating context

Raymond James said its October 12, 2026 upgrade followed meetings with BioMarin management and cited the rare-disease business as durable and diversified. The firm also projected 10.00 percent annual revenue growth and 16.00 percent annual growth in non-GAAP earnings per share through 2031, figures reported by Investing.com. Those projections are forward-looking analyst estimates rather than BioMarin reported results.

What the target means for valuation

The USD 109.00 target is materially above the October 20 Nasdaq price, while the company remains exposed to execution across rare-disease products and pipeline programs. The September settlement adds a royalty stream tied to future sales, but the filing does not state a guaranteed payment amount.

BioMarin price at Lang & Schwarz

At Lang & Schwarz, BioMarin stock was trading at EUR 49.79 on October 20, 2026 at 7:20 p.m. CEST. The Nasdaq quote was USD 55.90 at 1:27 p.m. ET on the same date. The further course of trading is shown by the continuously updated real-time quote of BioMarin Pharmaceutical stock.